Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 2Phase 1/2 2Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Melanoma 2

Interventions

Nivolumab 10pembrolizumab 6Ipilimumab 6Niacinamide 3Magnetic Resonance Spectroscopy 3Itraconazole 3Cyclophosphamide 3Biopsy 3resiquimod 2encorafenib 2durvalumab 2calcipotriene 2binimetinib 2aldesleukin 2Radiotherapy 2Oncolytic Virotherapy 2Niacin 2MART-1 Antigen 2Interleukin-2 2Imiquimod 2HhAntag691 2Fluorouracil 2Ascorbic Acid 2urelumab 1tremelimumab 1tetraethylpyrazine 1technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran 1relatlimab 1montanide ISA 51 1glucopyranosyl lipid-A 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × resiquimod × Dermatologic × Clear all
NCT01748747 2018-10-09

Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery

Mayo Clinic

Phase EARLY_PHASE1 Completed
30 enrolled
Dermatologic

Melanoma

NCT00470379 2014-10-31

Vaccine Therapy and Resiquimod in Treating Patients With Stage II, Stage III, or Stage IV Melanoma That Has Been Completely Removed by Surgery

Mayo Clinic

Phase EARLY_PHASE1 Completed
30 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡